Review article: colorectal cancer chemotherapy

被引:59
作者
Gill, S
Thomas, RR
Goldberg, RM
机构
[1] Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC 27599 USA
[2] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[3] Evanston Northwestern Healthcare, Div Haematol Oncol, Evanston, IL 60208 USA
[4] Northwestern Univ, Sch Med, Dept Med, Evanston, IL 60208 USA
关键词
HIGH-DOSE LEUCOVORIN; DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY; PROTRACTED-INFUSION FLUOROURACIL; QUALITY-OF-LIFE; PHASE-II TRIAL; RANDOMIZED-TRIAL; INTRAVENOUS FLUOROURACIL; 1ST-LINE TREATMENT; PLUS LEUCOVORIN; MICROSATELLITE INSTABILITY;
D O I
10.1046/j.1365-2036.2003.01735.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Colorectal cancer is a leading cause of cancer death world-wide. There have been important advances in the chemotherapeutic management of colorectal cancer as a result of a deliberate collaborative process of well-designed clinical trials. From the earlier standard of 5-fluorouracil-based therapy alone, the recent availability of newer agents, including capecitabine, irinotecan and oxaliplatin, has significantly expanded the options available for the management of patients with advanced colorectal cancer, with consequent improvements in survival. For patients with resected, high-risk, localized disease, adjuvant systemic chemotherapy improves survival. The identification of new chemotherapy regimens, the use of predictive testing and the integration of novel targeted therapies with cytotoxic chemotherapies are areas of active clinical investigation. A review of the chemotherapeutic management of colorectal cancer is presented.
引用
收藏
页码:683 / 692
页数:10
相关论文
共 73 条
  • [1] Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen
    André, T
    Louvet, C
    Raymond, E
    Tournigand, C
    de Gramont, A
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (11) : 1251 - 1253
  • [2] [Anonymous], 1999, LANCET, V354, P1045
  • [3] Becouarn Y, 1998, SEMIN ONCOL, V25, P23
  • [4] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [5] RANDOMIZED COMPARISON OF 2 SCHEDULES OF FLUOROURACIL AND LEUCOVORIN IN THE TREATMENT OF ADVANCED COLORECTAL-CANCER
    BUROKER, TR
    OCONNELL, MJ
    WIEAND, HS
    KROOK, JE
    GERSTNER, JB
    MAILLIARD, JA
    SCHAEFER, PL
    LEVITT, R
    KARDINAL, CG
    GESME, DH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) : 14 - 20
  • [6] Buyse M, 1996, J NATL CANCER I, V88, P252
  • [7] Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
    Carmichael, J
    Popiela, T
    Radstone, D
    Falk, S
    Borner, M
    Oza, A
    Skovsgaard, T
    Munier, S
    Martin, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3617 - 3627
  • [8] Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer
    Cocconi, G
    Cunningham, D
    Van Cutsem, E
    Francois, E
    Gustavsson, B
    van Hazel, G
    Kerr, D
    Possinger, K
    Hietschold, SM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) : 2943 - 2952
  • [9] Final results of a randomised trial comparing 'Tomudex'(R) (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer
    Cunningham, D
    Zalcberg, JR
    Rath, U
    Oliver, I
    vanCutsem, E
    Svensson, C
    Seitz, JF
    Harper, P
    Kerr, D
    PerezManga, G
    [J]. ANNALS OF ONCOLOGY, 1996, 7 (09) : 961 - 965
  • [10] Mature results from three large controlled studies with raltitrexed ('Tomudex')
    Cunningham, D
    [J]. BRITISH JOURNAL OF CANCER, 1998, 77 (Suppl 2) : 15 - 21